In short
A new clinical trial is investigating the use of VE202, a novel drug containing multiple strains of live bacteria, for the treatment of mild to moderate ulcerative colitis. This Phase 2 study aims to evaluate the efficacy and safety of VE202 in patients who have not previously received certain types of treatments for their condition. The trial will assess the drug's ability to improve endoscopic response and monitor any potential side effects over an 8-week treatment period.
At a glance
- Study Type
- Phase 2, randomized, double-blind, placebo-controlled
- Medication
- VE202 (capsule containing multiple strains of live bacteria)
- Condition
- Mild to moderate ulcerative colitis
- Primary Objectives
- Evaluate efficacy (endoscopic response) and safety
- Treatment Duration
- 8 weeks
- Key Inclusion Criteria
- Adults 18-75, UC diagnosis for ≥3 months, no prior biologic treatment
- Key Exclusion Criteria
- Active infections, recent antibiotic use, allergy to VE202 components
- Primary Endpoints
- Endoscopic response rate, treatment-related adverse events
What is VE202?
VE202 is an investigational drug being studied for the treatment of mild-to-moderate ulcerative colitis. It is a capsule containing live bacteria strains, specifically designed to target the digestive system. VE202 is also known by its sponsor product code JNJ-72537634.
The drug consists of multiple strains of live bacteria, including:
- Clostridia, cluster XIVA, strain relative Anaerostipes hominis, live
- Clostridia, cluster XIVA, strain relative Blautia coccoides, live
- Clostridia, cluster XIVA, strain relative Hungatella effluvii, live
- Bacilli, cluster XVIII, strain relative Thomasclavelia sp000508865, live
- And several other bacterial strains
Target Condition: Mild-to-Moderate Ulcerative Colitis
VE202 is being studied for the treatment of mild-to-moderate ulcerative colitis (UC). Ulcerative colitis is a type of inflammatory bowel disease (IBD) that causes inflammation and ulcers in the lining of the large intestine (colon) and rectum. Symptoms can include diarrhea, abdominal pain, and rectal bleeding.
How VE202 Works
VE202 is a type of treatment known as a live biotherapeutic product. It contains live bacteria that are thought to help restore balance to the gut microbiome - the community of microorganisms living in our digestive tract. In ulcerative colitis, this balance is often disrupted. By introducing beneficial bacteria, VE202 may help reduce inflammation and improve symptoms of UC.
Clinical Trial Details
VE202 is currently being studied in a Phase 2 clinical trial. This means that while it has shown promise in earlier studies, it is still being tested to determine its effectiveness and safety. Key details of the trial include:
- It is a randomized, double-blind, placebo-controlled study. This means that participants are randomly assigned to receive either VE202 or a placebo, and neither the participants nor the researchers know who is receiving which treatment.
- The treatment period is 8 weeks.
- The main goal is to evaluate how well VE202 improves the appearance of the colon lining (endoscopic response) after 56 days of treatment.
- The study is also assessing the safety of VE202.
Eligibility Criteria
To participate in this study, patients must meet certain criteria. Some key eligibility factors include:
- Age 18 to 75 years
- Diagnosed with ulcerative colitis at least 3 months before the study
- Have active mild to moderate UC, as determined by specific scoring systems
- Have not previously received certain types of treatments for UC (such as biologic agents)
There are also several exclusion criteria, such as having other digestive conditions or recent use of antibiotics.
Potential Benefits
While the effectiveness of VE202 is still being studied, the hope is that it may provide several benefits for people with mild-to-moderate ulcerative colitis:
- Improvement in the appearance of the colon lining (endoscopic response)
- Reduction in UC symptoms, such as diarrhea and rectal bleeding
- A new treatment option for those who haven't responded well to other therapies
Safety Considerations
As with any investigational treatment, the safety of VE202 is a key focus of the clinical trial. The study is specifically monitoring for:
- Any serious side effects related to VE202
- Any moderate to severe side effects that may be related to the treatment
It's important to note that as an investigational treatment, not all potential side effects of VE202 may be known at this time. Patients considering participating in the trial should discuss the potential risks and benefits with their healthcare provider.